Talimogene laherparepvec induces durable response of regionally advanced Merkel cell carcinoma in 4 consecutive patients

Brian C Westbrook; T Graham Norwood; Nina L J Terry; Svetlana B McKee; Robert M Conry

doi:10.1016/j.jdcr.2019.06.034

Talimogene laherparepvec induces durable response of regionally advanced Merkel cell carcinoma in 4 consecutive patients

JAAD Case Rep. 2019 Aug 29;5(9):782-786. doi: 10.1016/j.jdcr.2019.06.034. eCollection 2019 Sep.

Authors

Brian C Westbrook¹, T Graham Norwood¹, Nina L J Terry², Svetlana B McKee³, Robert M Conry³

Affiliations

¹ University of Alabama at Birmingham School of Medicine, Birmingham, Alabama.
² Department of Radiology, General Radiology and Cardiopulmonary Section, University of Alabama at Birmingham Medicine, Birmingham, Alabama.
³ Division of Hematology Oncology, University of Alabama at Birmingham, Birmingham, Alabama.

No abstract available

Keywords: CR, complete response; CT, computed tomography; FDA, US Food and Drug Administration; ICB, immune checkpoint blockade; MCC, Merkel cell carcinoma; MCPyV, Merkel cell polyomavirus; Merkel cell carcinoma; ORR, objective response rate; PD-L1, programmed death ligand 1; PET, positron emission tomography; PFS, progression-free survival; SUV, standardized uptake values; TVEC, talimogene laherparepvec; advanced Merkel cell carcinoma; durable response; immunotherapy; oncolytic virus; regionally advanced Merkel cell carcinoma; talimogene laherparepvec.

Publication types

Case Reports